| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7723361 | BRISTOL-MYERS | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide |
Mar, 2013
(11 years ago) | |
| US8143283 | BRISTOL-MYERS | Methods for treating blood-born tumors with thalidomide |
Mar, 2013
(11 years ago) | |
| US6235756 | BRISTOL-MYERS | Methods and compositions for inhibition of angiogenesis by thalidomide |
Mar, 2013
(11 years ago) | |
| US5629327 | BRISTOL-MYERS | Methods and compositions for inhibition of angiogenesis |
May, 2014
(9 years ago) | |
| US7435745 | BRISTOL-MYERS | Methods and compositions for inhibition of angiogenesis |
Nov, 2017
(6 years ago) | |
| US7874984 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US8589188 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6561976 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6908432 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6045501 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US8204763 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US8626531 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US7959566 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6315720 | BRISTOL-MYERS | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(3 years ago) | |
| US7141018 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6755784 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US8315886 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6561977 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6869399 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US7230012 | BRISTOL-MYERS | Pharmaceutical compositions and dosage forms of thalidomide |
Dec, 2023
(4 months ago) | |
Thalomid is owned by Bristol-Myers.
Thalomid contains Thalidomide.
Thalomid has a total of 20 drug patents out of which 20 drug patents have expired.
Expired drug patents of Thalomid are:
- US7723361
- US8143283
- US6235756
- US5629327
- US7435745
- US7874984
- US8589188
- US6561976
- US6908432
- US6045501
- US8204763
- US8626531
- US7959566
- US6315720
- US7141018
- US6755784
- US8315886
- US6561977
- US6869399
- US7230012
Thalomid was authorised for market use on 16 July, 1998.
Thalomid is available in capsule;oral dosage forms.
Thalomid can be used as method for delivering a drug to a patient in need of the drug, while avoiding the occurrence of an adverse side effect known or suspected of being caused by said drug, use of thalidomide in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma, acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl), use in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma, treatment of male patient having a disease or condition responsive to a teratogenic drug, use of thalidomide in treatment of cutaneous manifestations of erythema nodosum leprosum (enl), use of thalomid (thalidomide) for the treatment of multiple myeloma, approval for marketing only under a special restriction program approved by fda called 'system for thalidomide education and prescribing safety' (s.t.e.p.s.), use of thalidomide while preventing the exposure of a fetus or other contraindicated individual to thalidomide.
The generics of Thalomid are possible to be released after 09 December, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 23, 2013 |
Drugs and Companies using
THALIDOMIDE ingredient
Market Authorisation Date:
16 July, 1998Treatment:
Use of thalidomide in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma; Use of thalomid (thalidomide) for the treatment of multiple myeloma; Use in co...Dosage:
How can I launch a generic of THALOMID before its drug patent expiration?
More Information on Dosage
THALOMID family patents
